Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04110054 · ClinicalTrials.gov registry record · Phase 2
Evaluation of S-600918 in Adults With Refractory Chronic Cough
A Phase 2 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 406
- Enrollment target
NCT04110054 is a Phase 2 study that has completed, run by Shionogi. The registered enrollment target is 406 participants.
The verdict
NCT04110054, a Phase 2 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 406 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.
Interventions
- DRUG S-600918
- DRUG Placebo to S-600918
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04110054
The ClinicalTrials.gov registry entry for NCT04110054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S-600918 is the first listed.
NCT04110054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04110054 about?
NCT04110054 is a clinical study titled "Evaluation of S-600918 in Adults With Refractory Chronic Cough". The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.
What is the current status of trial NCT04110054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 406 participants. The study started on 2020-02-13. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT04110054?
The interventions under investigation include: S-600918 (DRUG), Placebo to S-600918 (DRUG).
Who is sponsoring clinical trial NCT04110054?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.